MD4629B1 - Metode de tratament a fibrozei şi cancerului - Google Patents

Metode de tratament a fibrozei şi cancerului

Info

Publication number
MD4629B1
MD4629B1 MDA20150076A MD20150076A MD4629B1 MD 4629 B1 MD4629 B1 MD 4629B1 MD A20150076 A MDA20150076 A MD A20150076A MD 20150076 A MD20150076 A MD 20150076A MD 4629 B1 MD4629 B1 MD 4629B1
Authority
MD
Moldova
Prior art keywords
cancers
fibrosis
treatment
methods
carboxydimethylmethyloxyphenyl
Prior art date
Application number
MDA20150076A
Other languages
English (en)
Russian (ru)
Other versions
MD20150076A2 (ro
Inventor
Реми Анф
Хам
Роберт Вальчак
Бенуа Ноэль
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MD20150076A2 publication Critical patent/MD20150076A2/ro
Publication of MD4629B1 publication Critical patent/MD4629B1/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la medicină, şi anume la utilizarea compusului 1-[4-metiltiofenil]-3-[3,5-dimetil-4-carboxidimetilmetiloxifenil]prop-2-en-1-onă pentru tratamentul bolilor fibrotice şi cancerului.Secvenţe: 20
MDA20150076A 2013-01-18 2014-01-20 Metode de tratament a fibrozei şi cancerului MD4629B1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305067 2013-01-18
PCT/EP2014/051060 WO2014111584A1 (en) 2013-01-18 2014-01-20 Methods of treatment of fibrosis and cancers

Publications (2)

Publication Number Publication Date
MD20150076A2 MD20150076A2 (ro) 2015-11-30
MD4629B1 true MD4629B1 (ro) 2019-05-31

Family

ID=47628079

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150076A MD4629B1 (ro) 2013-01-18 2014-01-20 Metode de tratament a fibrozei şi cancerului

Country Status (26)

Country Link
US (2) US20150352065A1 (ro)
EP (1) EP2948137B1 (ro)
JP (1) JP6218854B2 (ro)
KR (1) KR102196277B1 (ro)
CN (1) CN105120855B (ro)
AU (1) AU2014206781B2 (ro)
CA (1) CA2897258C (ro)
CY (1) CY1121156T1 (ro)
DK (1) DK2948137T3 (ro)
EA (1) EA031718B1 (ro)
ES (1) ES2702038T3 (ro)
HK (1) HK1214773A1 (ro)
HU (1) HUE042569T2 (ro)
IL (1) IL239715B (ro)
LT (1) LT2948137T (ro)
MD (1) MD4629B1 (ro)
MX (1) MX361565B (ro)
NZ (1) NZ709420A (ro)
PH (1) PH12015501566A1 (ro)
PL (1) PL2948137T3 (ro)
PT (1) PT2948137T (ro)
SG (1) SG11201505281PA (ro)
SI (1) SI2948137T1 (ro)
TR (1) TR201819042T4 (ro)
WO (1) WO2014111584A1 (ro)
ZA (1) ZA201505151B (ro)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361565B (es) 2013-01-18 2018-12-11 Genfit Metodos de tratamiento de fibrosis y canceres.
JP2019505598A (ja) * 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ii, エルエルシー Smad7の阻害を用いて、腸線維症を治療する方法
EP3612176A1 (en) * 2017-04-18 2020-02-26 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
US20210309608A1 (en) 2018-08-03 2021-10-07 Genfit Elafibranor salts
GB201901507D0 (en) * 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
MX2022009778A (es) 2020-02-10 2022-09-09 Genfit Polimorfos de elafibranor.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736677B2 (en) 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
KR101865677B1 (ko) * 2009-11-26 2018-07-16 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
ES2384060B1 (es) * 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
MX361565B (es) 2013-01-18 2018-12-11 Genfit Metodos de tratamiento de fibrosis y canceres.

Also Published As

Publication number Publication date
IL239715A0 (en) 2015-08-31
ES2702038T3 (es) 2019-02-27
US10792277B2 (en) 2020-10-06
PH12015501566B1 (en) 2015-09-21
US20170239213A1 (en) 2017-08-24
JP6218854B2 (ja) 2017-10-25
KR20150114497A (ko) 2015-10-12
CA2897258C (en) 2021-02-02
CY1121156T1 (el) 2020-05-29
HK1214773A1 (zh) 2016-08-05
EP2948137A1 (en) 2015-12-02
KR102196277B1 (ko) 2020-12-29
MX361565B (es) 2018-12-11
TR201819042T4 (tr) 2019-01-21
HUE042569T2 (hu) 2019-07-29
CN105120855B (zh) 2019-05-07
IL239715B (en) 2019-06-30
EP2948137B1 (en) 2018-11-14
PT2948137T (pt) 2018-12-20
US20150352065A1 (en) 2015-12-10
EA201591345A1 (ru) 2015-11-30
PH12015501566A1 (en) 2015-09-21
MX2015009251A (es) 2015-10-15
NZ709420A (en) 2020-04-24
DK2948137T3 (en) 2019-01-07
ZA201505151B (en) 2016-07-27
LT2948137T (lt) 2018-12-27
CA2897258A1 (en) 2014-07-24
AU2014206781B2 (en) 2018-08-23
PL2948137T3 (pl) 2019-02-28
WO2014111584A1 (en) 2014-07-24
EA031718B1 (ru) 2019-02-28
JP2016506913A (ja) 2016-03-07
SI2948137T1 (sl) 2019-01-31
CN105120855A (zh) 2015-12-02
SG11201505281PA (en) 2015-08-28
AU2014206781A1 (en) 2015-07-16
MD20150076A2 (ro) 2015-11-30

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
TW201613901A (en) New compounds
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
HK1213925A1 (zh) 用於治療癌症的涉及抗密蛋白 抗體的組合療法
MX2021005471A (es) Particulas inmunomodificadoras para el tratamiento de la inflamacion.
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MY188139A (en) Sodium channel modulators for the treatment of pain
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
PH12015501566A1 (en) Methods of treatment of fibrosis and cancers
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
SI2771329T1 (sl) Nove disubstituirane 3,4-diamino-3-ciklobuten-1,2-dion-spojine za uporabo pri tretiranju kemokin mediiranih bolezni
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
SA515360377B1 (ar) نظائر خيمرية من سوماتوستاتين- دوبامين

Legal Events

Date Code Title Description
FC9A Refusal of application (patent for invention)
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)